摘要
随着降糖药物不断研发及DM治疗理念更新,新型降糖药包括GLP-1受体激动剂、SGLT2i、DPP-4i及新型胰岛素类似物制剂在临床治疗中地位不断升高。不同种族敏感性可影响药物疗效和安全性。本文对新型降糖药治疗中的种族差异进行评述。
With the continuous development of hypoglycemic drugs and the update of diabetes mellitus(DM)treatment concepts,the status of new hypoglycemic drugs,including GLP-1RA,SGLT2i,DPP-4i,and new insulin analogues,is constantly increasing in clinical treatment.The sensitivity of different races can affect the efficacy and safety of drugs.This article reviews the research progress on racial differences in the treatment of new hypoglycemic drugs.
作者
蔡晓凌
林矗
吕芳
李媛媛
宋翔
纪立农
CAI Xiaoling;LIN Chu;LYU Fang(Department of Endocrinology,Peking University People's Hospital,Beijing 100044,China)
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2023年第6期476-480,共5页
Chinese Journal of Diabetes
关键词
糖尿病
2型
新型降糖药
种族差异
Diabetes mellitus,type 2
New hypoglycemic drugs
Racial differences